[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355286-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355286-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","exploring-the-optimal-cutoff-point-and-genomic-characteristics-for-parp-inhibitor-maintenance-therapy-in-early-recurrence-of-ovarian-cancer","Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer","","Ovarian cancer remains the deadliest gynecological malignancy, and PARP inhibitor maintenance therapy improves outcomes yet cannot prevent all recurrences. A lack of an established definition for early recurrence during PARP inhibitor maintenance limits prognosis assessment and treatment planning. This retrospective study analyzed first-line PARP inhibitor maintenance patients from March 2020 to April 2024 to determine an optimal cutoff, evaluate clinical risk factors, and characterize genomic alterations using targeted sequencing.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-the-optimal-cutoff-point-and-genomic-characteristics-for-parp-inhibitor-maintenance-therapy-in-early-recurrence-of-ovarian-cancer/355286/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-the-optimal-cutoff-point-and-genomic-characteristics-for-parp-inhibitor-maintenance-therapy-in-early-recurrence-of-ovarian-cancer/355286.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient population and treatment setting were analyzed in the study?","Question",{"text":63,"@type":64},"The retrospective study included ovarian cancer patients receiving first-line PARP inhibitor maintenance therapy between March 2020 and April 2024.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the optimal cutoff point for early recurrence determined?",{"text":68,"@type":64},"The optimal cutoff point was calculated using the maximally selected rank statistic, and practical clinical convenience led to defining it as 12 months.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors and genomic features were associated with early recurrence?",{"text":72,"@type":64},"Early recurrence was linked to receiving neoadjuvant chemotherapy, maximal cytoreductive surgery with residual disease, and not achieving complete response. Early recurrence cases also showed frequent mutations in MTOR, SMARCB1 and ZNF217, along with higher tumor mutational burden.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355286,1791131624,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Ye etal. Journal of Ovarian Research (2026) 19:99 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-02010-3](https://doi.org/10.1186/s13048-026-02010-3)  \nRESEARCH Open Access  \nExploring the optimal cutoff point   \nand genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer  \nLuxin Ye1†, Yourong Chen1†, Yan Chen2†, Qian Zhao1, Xianzhong Cheng1, Xuening Wang1, Xia Xu3, Wenwen Guo4, Xiaoxiang Chen1* and Jing Ni 1*  \nAbstract  \nBackground Ovarian cancer is the deadliest gynecological malignancy. The advent of poly-adenosine diphosphate ribose polymerase (PARP) inhibitors has transformed the treatment paradigm for ovarian cancer, significantly improving survival outcomes. However, some patients inevitably experience disease recurrence during maintenance therapy with PARP inhibitor. Currently, there is no established definition for early recurrence with PARP inhibitor. Methods This retrospective study analyzed ovarian cancer patients who received first-line PARP inhibitor maintenance therapy between March 2020 and April 2024. The optimal cutoff point for early recurrence was calculated using the maximally selected rank statistic. The logistic regression was employed to evaluate risk factors for early recurrence. Targeted sequencing of 437 cancer-related genes was performed on 37 ovarian cancer samples. Results Among the 174 enrolled patients, 59 (33 . 9%) experienced recurrence. The optimal cutoff point for defining early recurrence was 11.37 months (median progression-free survival [PFS], 9.0 vs. not reached [NR], P \u003C 0. 001) . For clinical convenience, this cutoff point was defined as 12 months. High-risk predictors for early recurrence included receiving neoadjuvant chemotherapy, maximal cytoreductive surgery with residual disease, and not achieving complete response (CR) to chemotherapy. Patients with early recurrence exhibit frequent mutations in MTOR, SMARCB1 and ZNF217, and have a higher tumor mutational burden (TMB) .  \nConclusions According to the results of this study, the optimal cutoff point for defining early recurrence was 12 months. Identifying high-risk predictors for early recurrence can facilitate prognosis stratification and guide treatment decisions.  \n†Luxin Ye, Yourong Chen andYan Chen contributed equally to this work.  \n*Correspondence: Xiaoxiang Chen[cxxxxcyd@gmail.com](cxxxxcyd@gmail.com)[ ](cxxxxcyd@gmail.com)Jing Ni [nijingwulin@126.com](nijingwulin@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nYe et al. Journal of Ovarian Research (2026) 19:99 Page 2 of 14  \nKeywords Ovarian cancer, PARP inhibitor, Cutoff point, Early recurrence, Resistance  \nBackground  \nOvarian cancer is the most deadly gynecological malignancy [1]. Ovarian cancer is frequently diagnosed at an advanced stage due t","cbCaioUNeLQxJIVF","https://ap.wps.com/l/cbCaioUNeLQxJIVF","pdf",2743916,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n## Keywords\n# Background\n## Disease burden and maintenance therapy context\n## Need for updated early recurrence definition","[{\"question\":\"What patient population and treatment setting were analyzed in the study?\",\"answer\":\"The retrospective study included ovarian cancer patients receiving first-line PARP inhibitor maintenance therapy between March 2020 and April 2024.\"},{\"question\":\"How was the optimal cutoff point for early recurrence determined?\",\"answer\":\"The optimal cutoff point was calculated using the maximally selected rank statistic, and practical clinical convenience led to defining it as 12 months.\"},{\"question\":\"What factors and genomic features were associated with early recurrence?\",\"answer\":\"Early recurrence was linked to receiving neoadjuvant chemotherapy, maximal cytoreductive surgery with residual disease, and not achieving complete response. Early recurrence cases also showed frequent mutations in MTOR, SMARCB1 and ZNF217, along with higher tumor mutational burden.\"}]","Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer | PDF",1790117369,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/587aa0b11326ebbadd61f80b0855cf30.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49e6038b24a7c41ce648332287bedfa8.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/78d6d9ba44b32e6dfcd16bb68e01513c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0187e50e05b886b2f888fa31584456a7.webp",980,1306]